Post-Herpetic Neuralgia: A Complication of Shingles
When a person develops shingles, a painful rash develops. Usually, the pain resolves after the shingles has healed. But post-herpetic neuralgia can cause pain that lasts for months or years. The pain is usually localized to the area of the rash.Who Develops Post-Herpetic Neuralgia?
Approximately 20 percent of people with shingles develop post-herpetic neuralgia. Anyone can develop post-herpetic neuralgia, but the chances of developing it increase with age.What Are the Symptoms?
- Pain, ranging from mild to severe
- Increased sensitivity to touch
- Sharp pain
- Burning pain
- Throbbing
- Increased sensitivity to temperature changes
- Numbness
- Itching
What Is the Treatment?
- Topical lidocaine Your doctor may prescribe patches that contain lidocaine, a pain-relieving (anesthetic) medication. These are absorbed directly through the skin.
- Antidepressants Certain antidepressants can decrease the pain. The type of antidepressant that is most commonly prescribed is called a tricyclic antidepressant.
- Anticonvulsants Medications that are used to control seizures can be effective treatments for post-herpetic neuralgia. Commonly used anticonvulsants for post-herpetic neuralgia include Neurontin (gabapentin) and Lyrica (pregabalin).
- Capsaicin cream Capsaicin cream is made from the seeds of hot peppers. It is sometimes used for the treatment of post-herpetic neuralgia. However, it causes skin irritation for some people.
- Opioid analgesics Opioid medications such as Oxycodone and morphine can help to decrease the pain.
- TENS Transcutaneous electrical nerve stimulation is a form of treatment that can decrease the pain. Electrodes are applied onto the skin and small electrical currents are delivered.
Sources:
Choo PW et al. Risk Factors for Post herpetic Neuralgia. Archives of Internal MedicineJune 9 1997;157(11(:1217-24 Johnson RW. Herpes Zoster and Post Herpetic Neuralgia: Optimal Treatment Drugs AgingFeb 1997;10920:80-94 Freynhagen et al. Efficacy of pregabalin in neuropathic pain evaluated in a 12-week, randomized, double-blind, multicentre, placebo-controlled trial of flexible and fixed-dose regimens. Pain. June 2005;115(3):254-63
